Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 7, 2017

Primary Completion Date

December 31, 2022

Study Completion Date

July 17, 2026

Conditions
Recurrent Glioblastoma
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

Cediranib

Given PO

DRUG

Cediranib Maleate

Given PO

DRUG

Olaparib

Given PO

Trial Locations (27)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

27710

Duke University Medical Center, Durham

33612

Moffitt Cancer Center, Tampa

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

63136

Siteman Cancer Center at Christian Hospital, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

80045

UCHealth University of Colorado Hospital, Aurora

92093

UC San Diego Moores Cancer Center, La Jolla

06418

Smilow Cancer Hospital-Derby Care Center, Derby

06824

Smilow Cancer Hospital Care Center-Fairfield, Fairfield

06437

Smilow Cancer Hospital Care Center - Guilford, Guilford

06105

Smilow Cancer Hospital Care Center at Saint Francis, Hartford

06510

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

06520

Yale University, New Haven

06477

Smilow Cancer Hospital-Orange Care Center, Orange

06790

Smilow Cancer Hospital-Torrington Care Center, Torrington

06611

Smilow Cancer Hospital Care Center-Trumbull, Trumbull

06708

Smilow Cancer Hospital-Waterbury Care Center, Waterbury

06385

Smilow Cancer Hospital Care Center - Waterford, Waterford

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Dana-Farber Cancer Institute, Boston

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH